Pipeline

Pipeline


Product / Indication Pre Clinical Phase 1 Phase 2 Phase 3 NDA Approved
TAVALISSE™*
Indication: Immune Thrombocytopenia
Target: SYK
  • 100%
Fostamatinib - AIHA
Indication: Autoimmune Hemolytic Anemia
Target: SYK
  • 50%
Fostamatinib - IgAN
Indication: IgA Nephropathy
Target: SYK
  • 50%
R835
Indication: Immune Disease
Target: IRAK
  • 25%
BGB324 - BerGenBio
Indication: Cancer
Target: AXL
  • 43%
ATI-50001 & 50002 - Aclaris
Indication: Dermatology
Target: JAK
  • 43%
DS-3032 - Daiichi Sankyo
Indication: Cancer
Target: MDM2
  • 37%
TGF-beta Inhibitors - BMS
Indication: Cancer/Immunotherapy
Target: TGF-beta
  • 18%
AZD0449 - AstraZeneca
Indication: Chronic Asthma
Target: JAK
  • 15%
Partner-sponsored Trials
Company-sponsored Trials



* Please see the Tavalisse full Prescribing Information at www.tavalisse.com